|1.||Bussel, James B: 13 articles (10/2015 - 01/2011)|
|2.||Erickson-Miller, Connie L: 6 articles (01/2012 - 06/2007)|
|3.||Theodore, Dickens: 5 articles (10/2015 - 06/2012)|
|4.||Kuter, David J: 5 articles (10/2015 - 02/2008)|
|5.||Ghanima, Waleed: 5 articles (05/2014 - 10/2011)|
|6.||Godeau, Bertrand: 4 articles (12/2015 - 08/2012)|
|7.||Bailey, Christine K: 4 articles (10/2015 - 04/2009)|
|8.||Bakshi, Kalpana K: 4 articles (10/2015 - 01/2014)|
|9.||Orazi, Attilio: 4 articles (07/2015 - 10/2011)|
|10.||Levine, Ross L: 4 articles (09/2012 - 01/2007)|
07/01/2015 - "Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults."
01/01/2011 - "What's new in the management of chronic primary immune thrombocytopenia in adults and the use of thrombopoietin receptor agonists."
06/01/2014 - "The temporary use of thrombopoietin-receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. "
06/19/2014 - "A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia."
10/24/2015 - "Thrombopoietin-receptor agonists in children with immune thrombocytopenia."
|2.||Thrombocytopenic Purpura (Thrombopenic Purpura)
07/01/2011 - "Thrombopoietin receptor agonists are a new class of compounds licenced for the treatment of immune thrombocytopenic purpura. "
03/01/2009 - "[Thrombopoietin-receptor agonists: a revolution in the therapeutic strategies of immune thrombocytopenic purpura?]."
01/01/2009 - "New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents."
02/01/2008 - "New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura."
09/01/2012 - "Some thrombopoietin receptor-agonists (TPR-As) have been developed and shown to be highly effective in the treatment of immune thrombocytopenic purpura (ITP). "
|3.||Myelodysplastic Syndromes (Myelodysplastic Syndrome)
12/01/2014 - "Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials."
03/01/2011 - "Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome."
10/29/2009 - "Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome."
11/01/2014 - "A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine."
09/01/2006 - "Amgen Inc is developing AMG-531, a peptibody that binds to the thrombopoietin receptor Mpl, for the potential treatment of immune thrombocytopenic purpura (ITP), chemotherapy-induced thrombocytopenia (CIT) and thrombocytopenia in myelodysplastic syndrome (MDS). "
|4.||Primary Myelofibrosis (Myelosclerosis)
05/01/2014 - "Annual/biannual follow-up with bone marrow biopsies is, therefore, recommended in patients being treated with thrombopoietin-receptor agonists in order to enable prompt discontinuation of these drugs should grades 2/3 myelofibrosis develop. "
05/01/2014 - "The median duration of treatment with thrombopoietin-receptor agonists to last bone marrow biopsies was 29 months; patients who had two or more biopsies significantly more frequently had myelofibrosis grades 2/3 in the last bone marrow biopsies as compared to the first. "
05/01/2014 - "Bone marrow fibrosis has been reported in patients receiving thrombopoietin-receptor agonists. "
05/17/2012 - "Decreased expression of the thrombopoietin receptor (TPOR or MPL) on the cell surface of platelets and megakaryocytes is an established feature of and myelofibrosis; however, the exact mechanism responsible for this phenomenon has gone largely unexplained. "
01/01/2012 - "Anecdotal reports have raised concerns about a possible association between therapy with thrombopoietin receptor agonists and an increase in bone marrow fibrosis. "
05/01/2014 - "Discontinuation of thrombopoietin-receptor agonists may prevent development of clinical manifestations by stopping progression of fibrosis in grade 2/3."
12/01/2014 - "This is a phase II multicentre study to investigate the efficacy and safety of avatrombopag (E5501), an investigational second-generation thrombopoietin receptor agonist, administered one week prior to elective procedures in patients with thrombocytopenia secondary to cirrhosis. "
07/08/2015 - "It may be better to use thrombopoietin-receptor agonists, which have been tested as a treatment for cirrhosis-related thrombocytopenia, in combination with anti-platelet drugs to reduce the risk of venous thrombosis. "
04/01/2009 - "Furthermore, cooperation between OTT-MAL and an activating mutation of the thrombopoietin receptor myeloproliferative leukemia virus oncogene (MPL) efficiently induced a short-latency AMKL that recapitulated all the features of human AMKL, including megakaryoblast hyperproliferation and maturation block, thrombocytopenia, organomegaly, and extensive fibrosis. "
05/01/2015 - "Fibrosis has been reported in some patients with immune thrombocytopenia (ITP) treated with thrombopoietin receptor agonists (TPO-RA). "
|1.||Inosine Triphosphate (ITP)
|4.||4,5,6,7- tetrahydroisoxazolo(4,5- c)pyridin- 3- ol (THPO)
|5.||Erythropoietin Receptors (Erythropoietin Receptor)
|6.||Thrombopoietin (c-mpl Ligand)
|8.||Adrenal Cortex Hormones (Corticosteroids)
|1.||Hematopoietic Stem Cell Transplantation
|3.||Combination Drug Therapy (Combination Chemotherapy)
|5.||Drug Therapy (Chemotherapy)